Mantle Cell Lymphoma (MCL) Recruiting Phase 3 Trials for Rituximab (DB00073)

Also known as: Lymphoma, Mantle-Cell / Mantle Cell Lymphoma / Mantle-Cell Lymphoma / Lymphoma, Mantle- Cell / Lymphoma, Mantle Cell / Mantle-Cell Lymphomas / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS / Mantle cell lymphomas

IndicationStatusPhase
DBCOND0071979 (Mantle Cell Lymphoma (MCL))Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02972840A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell LymphomaTreatment
NCT01865110R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCLTreatment
NCT02858258ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell LymphomaTreatment
NCT03267433Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete RemissionTreatment